HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cranberry Supplements Can Prevent Or Delay Recurring Cystitis – Report

Executive Summary

Herbal cranberry supplements can prevent or delay recurrences of uncomplicated cystitis in women, says a report published by the German Institute for Quality and Efficiency in Health Care.

You may also be interested in...



‘Little To No Evidence’ To Support D-Mannose Supplementation For UTIs – Cochrane Review

Evidence for or against supplementation with D-mannose, a monosaccharide naturally found in fruits like cranberries, to prevent or treat acute or recurrent urinary tract infections is found wanting by a scientific review recently published in the Cochrane Library. 

US FDA Again Stops At Qualified Health Claim For Supplements: Cranberry Reduces UTI Risk

FDA intends to exercise enforcement discretion regarding QHCs about the association between reduced risk of recurrent UTI and use of supplements with at least 500 mg cranberry fruit powder and of cranberry juice beverages containing at least 27% cranberry juice.

Once-Daily Use Factored In US FDA Decision On Minimum Cranberry Dose For UTI Claim

In decision on Ocean Spray’s citizen petition, FDA says qualified health claims for cranberry to reduce the risk of recurrent urinary tract infections it will allow, under enforcement discretion, for use with supplements must specify a dose of at least 500 mg.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel